![Daniel O’Connell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Daniel O’Connell
Direttore/Membro del Consiglio presso Aristea Therapeutics, Inc.
Posizioni attive di Daniel O’Connell
Società | Posizione | Inizio | Fine |
---|---|---|---|
Aristea Therapeutics, Inc.
![]() Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA. | Direttore/Membro del Consiglio | 24/08/2022 | - |
Storia della carriera di Daniel O’Connell
Precedenti posizioni note di Daniel O’Connell
Società | Posizione | Inizio | Fine |
---|---|---|---|
LOGICBIO THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/06/2017 | 10/12/2020 |
Independent Dir/Board Member | 01/06/2017 | 10/12/2020 | |
ARIX BIOSCIENCE PLC | Direttore degli Investimenti | 01/10/2016 | 01/07/2019 |
PreciThera, Inc.
![]() PreciThera, Inc. Pharmaceuticals: MajorHealth Technology Precithera, Inc. engages in drug development business. The firm focuses on the design and the development of biological agents for the treatment of orphan diseases. The company was founded by Philippe Crine and Susan Schiavi on May 26, 2016 and is headquartered in Outremont, Canada. | Direttore/Membro del Consiglio | 01/07/2017 | 01/07/2019 |
OrbiMed Advisors LLC
![]() OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds. | Corporate Officer/Principal | 01/03/2012 | 01/08/2016 |
OrbiMed Advisors Private Equity
![]() OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Analista di Private Equity | - | - |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/04/2020 | - |
Arisaph Pharmaceuticals, Inc.
![]() Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Corporate Officer/Principal | - | - |
Formazione di Daniel O’Connell
Massachusetts Institute of Technology | Undergraduate Degree |
Tufts University School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Regno Unito | 2 |
Canada | 2 |
Posizioni
Director/Board Member | 3 |
Corporate Officer/Principal | 3 |
Independent Dir/Board Member | 1 |
Settori
Health Technology | 6 |
Finance | 5 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
ARIX BIOSCIENCE PLC | Finance |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Aziende private | 6 |
---|---|
LogicBio Therapeutics, Inc.
![]() LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
OrbiMed Advisors LLC
![]() OrbiMed Advisors LLC Investment ManagersFinance OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds. | Finance |
PreciThera, Inc.
![]() PreciThera, Inc. Pharmaceuticals: MajorHealth Technology Precithera, Inc. engages in drug development business. The firm focuses on the design and the development of biological agents for the treatment of orphan diseases. The company was founded by Philippe Crine and Susan Schiavi on May 26, 2016 and is headquartered in Outremont, Canada. | Health Technology |
Arisaph Pharmaceuticals, Inc.
![]() Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Health Technology |
OrbiMed Advisors Private Equity
![]() OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
Aristea Therapeutics, Inc.
![]() Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA. | Health Technology |
- Borsa valori
- Insiders
- Daniel O’Connell
- Esperienza